Table 2.

Angiogenesis factors associated with TP53 mutations in selected and non-selected cancer cohorts.

		Univariate						Multivariate**
				Non-small cell lung carcinoma				Pan-cancer
		Breast carcinoma	Colon carcinoma	Adenocarcinoma	Squamous carcinoma	Glioblastoma	Pan-cancer	OR [95% CI]	P-value
Number of TP53-mutated samples (N)		292	227	253	145	44	2,670	2,670
LIGANDS	VEGFA expression	Increased p < .001	Increased p = .007	Increased p = .024	-	-	Increased p < .001	1.16 [1.10–1.22]	p < .001
	VEGFB expression	-	-	-	-	-	Increased p < .001	1.07 [1.02–1.28]	p = .007
	VEGFC expression	-	-	-	Decreased p = .030	-	Increased p = .038	1.07 [1.01–1.12]	p = .012
RECEPTORS	FLT1 [VEGFR1] expression	-	-	-	Decreased p = .035	-	Decreased p < .001	0.93 [0.86–1.00]	p = .049
	KDR [VEGFR2] expression	Decreased p = .003	-	-	Decreased p = .007	-	Decreased p < .001	0.86 [0.80–0.93]	p < .001
	NRP1 expression*	-	-	-	-	-	Decreased p < .001	-	-

7,525 tumors presenting a TP53 mutation were assessed – tumors with a TP53 mutation were compared to those without a TP53 mutation, within individual cohorts. All p-values ≤.05 were considered significant (Mann Whitney U Test) and are presented.

*NRP1 is a co-receptor interacting with VEGFR1 and VEGFR2.

**p-values ≤0.1 in univariate were selected for multivariate analysis.

Detailed calculations are given in Supplementary Table S1.

Abbreviations: “-“ = non-significant change; 95% CI = 95% confidence interval; N = number; OR = odds ratio.